Paratek Pharmaceuticals Stock Forecast, Price & News

+0.04 (+0.49 %)
(As of 04/13/2021 03:44 PM ET)
Today's Range
Now: $8.26
50-Day Range
MA: $7.43
52-Week Range
Now: $8.26
Volume15,778 shs
Average Volume475,671 shs
Market Capitalization$387.34 million
P/E RatioN/A
Dividend YieldN/A
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Paratek Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PRTK
Previous SymbolNASDAQ:TSPT
Year FoundedN/A



Sales & Book Value

Annual Sales$16.54 million
Book Value($1.19) per share


Net Income$-128,790,000.00
Net Margins-248.03%


Market Cap$387.34 million
Next Earnings Date5/10/2021 (Estimated)


Notable Monday Option Activity: PRTK, WBA, CTAS
December 21, 2020 |
Is PRTK A Good Stock To Buy Now?
December 11, 2020 |
See More Headlines


Overall MarketRank

1.51 out of 5 stars

Medical Sector

503rd out of 2,016 stocks

Pharmaceutical Preparations Industry

245th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
+0.04 (+0.49 %)
(As of 04/13/2021 03:44 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

Is Paratek Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Paratek Pharmaceuticals?

Wall Street analysts have given Paratek Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Paratek Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Paratek Pharmaceuticals

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its earnings results on Wednesday, February, 24th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.57. The specialty pharmaceutical company had revenue of $16.02 million for the quarter, compared to analyst estimates of $39.58 million.
View Paratek Pharmaceuticals' earnings history

How has Paratek Pharmaceuticals' stock been impacted by Coronavirus?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has increased by 111.8% and is now trading at $8.24.
View which stocks have been most impacted by COVID-19

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $166-177 million, compared to the consensus revenue estimate of $182.84 million.

What price target have analysts set for PRTK?

3 Wall Street analysts have issued 12-month price objectives for Paratek Pharmaceuticals' stock. Their forecasts range from $14.00 to $22.00. On average, they expect Paratek Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 106.3% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:
  • Mr. Michael F. Bigham CPA, M.B.A., CPA, MBA, Exec. Chairman (Age 63, Pay $881.68k)
  • Dr. Evan Loh, CEO & Director (Age 62, Pay $906.9k)
  • Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 54, Pay $672.21k)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 59, Pay $586k)
  • Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 46)
  • Mr. Jason Burdette, Sr. VP of Technical Operations
  • Mr. Ben Strain, VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
  • Ms. Christine R. Coyne M.B.A., VP of Marketing
  • Ms. Karen McGrath, Sr. VP of HR
  • Mr. Randall B. Brenner, Chief Devel. & Regulatory Officer (Age 48)

Who are some of Paratek Pharmaceuticals' key competitors?

What other stocks do shareholders of Paratek Pharmaceuticals own?

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $8.24.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals has a market capitalization of $386.40 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

Paratek Pharmaceuticals employs 101 workers across the globe.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is

Where are Paratek Pharmaceuticals' headquarters?

Paratek Pharmaceuticals is headquartered at 75 PARK PLAZA, BOSTON MA, 02116.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.